Prasol Chemicals Limited reported a 151% year-on-year increase in net profit to ₹61 crore for Q1FY27, driven by strong volume growth and favorable pricing dynamics. Revenue from operations surged 35.7% YoY to ₹433.6 crore, reflecting the company's first quarter as a listed entity following its September 2026 IPO.

The earnings call, held on September 29, 2026, and the subsequent transcript filed on October 5, 2026, highlighted that while geopolitical tensions in West Asia and Strait of Hormuz disruptions boosted margins through inventory gains, the underlying business performance remained healthy with mid-single-digit volume growth. Management guided for FY27 revenue of ₹1,550 crore to ₹1,650 crore and adjusted EBITDA of ₹240 crore to ₹250 crore, excluding non-recurring inventory and forex gains.

Financial performance highlights

The quarter witnessed significant margin expansion due to higher realizations on acetone-based products, a petrochemical derivative whose prices rose sharply amid global supply constraints. The company carried inventory procured at lower prices into this rising price environment, resulting in a one-time gross profit boost of approximately ₹25 crore.

Management clarified that the guidance for FY27 excludes the ₹25 crore inventory gain and ₹0.92 crore forex benefit seen in Q1, aiming for a normalized EBITDA margin range of 15% to 16% for the full year.

Strategic expansion and capacity utilization

Prasol Chemicals is executing a Phase 1 capital expenditure plan of ₹250 crore to ₹300 crore over the next two years, focused on debottlenecking existing capacities and adding new product lines. This investment is expected to generate an additional ₹500 crore to ₹550 crore in revenue at peak utilization. A Phase 2 expansion of similar magnitude is planned for new R&D-driven products with better margins.

The company operates two manufacturing units:

• Khopoli: 78,800 tonnes per annum capacity, running at optimum utilization.
• Mahad: 19,900 tonnes per annum capacity, which turned sustainably profitable in Q1FY27 after improving utilization from 13% in FY24 to 44% in FY26.

Recent acquisitions include 10 acres of land at Mahad, bringing the surplus land bank there to 20 acres, alongside 10-12 acres at Khopoli, ensuring flexibility for future greenfield expansions.

Product mix and global diversification

The revenue mix remains stable, with acetone-based specialty chemicals contributing nearly 40% and phosphorus-based chemicals contributing another 40% of revenue. The remaining 20% comes from other specialty chemicals. Exports accounted for 27% of total revenue in Q1FY27, supported by consignment stock points in Houston, Rotterdam, and Shanghai that enable just-in-time delivery.

Key growth drivers identified by management include:

• Antibacterial Drug: A new technology reducing production steps from 10 to 3.5, with mechanical completion expected by January 2027 and initial volumes exceeding 100 tonnes per month.
• Mining Chemicals: US-approved products entering the pipeline, with significant revenue contribution expected in the next 2-3 years.
• Lubricant Additives: Capacity expansion via debottlenecking expected to increase output by 50-70% within the next few months.

What the numbers show

A divergence exists between the reported Q1 margins and the management's full-year guidance. While Q1 EBITDA margin hit 20.8%, the FY27 guidance implies a normalized margin of 15-16%. This gap is explicitly attributed to the ₹25 crore inventory gain, which constitutes roughly 27.7% of the quarter's total EBITDA. Excluding this non-recurring item, the operational EBITDA would be approximately ₹65.3 crore, implying a margin of around 15.1%, which aligns closely with the guided range. This confirms that the headline margin expansion was largely transitory, though underlying volume growth remains robust.

Regulatory compliance and disclosures

The disclosure was filed with the National Stock Exchange of India and BSE Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Kiran Rajendra Agrawal, Company Secretary and Compliance Officer, signed the digital filing confirming the availability of the earnings call transcript on the company's website.

Prasol Chemicals Limited has submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information to the National Stock Exchange and BSE Limited.

The filing was made pursuant to Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The company stated that the code is framed under Regulation 8(1) of the same regulations.

Regulatory Compliance

Kiran Agrawal, Company Secretary and Compliance Officer of Prasol Chemicals, signed the intimation on September 16, 2026. The document confirms that the code has been placed on record with both exchanges.

The company noted that the detailed code can be accessed on its official website. No financial results or operational updates were included in this specific regulatory filing.